Efficacy of a seal-wing paclitaxel-eluting balloon catheters in the treatment of bare metal stent restenosis

Table 3 12-month clinical follow-up

		Seal-wing PEB	Iopromide-coated PEB	EES	p
		Seal-wing PEB	Iopromide-coated PEB	EES	Seal-wing vs. iopromide- PEB	Seal-wing PEB vs. EES
Patients/lesions, n		63/64	68/74	68/74
MACE all, n(%)		17 (26.98%)	7 (10.29%)	13 (19.12%)	0.003^a	0.102^a
CV death, n(%)		0	1 (1.47%)	1 (1.47%)	1.000^b	1.000^b
AIM, n(%)		4 (6.35%)	1 (1.47%)	1 (1.47%)	0.468^b	0.468^b
TVR, n(%)		13 (20.63%)	5 (7.35%)	11 (16.18%)	0.009^a	0.360^a
Event-free survivors, n(%)		46 (73.02%)	61 (89.71%)	55 (80.88%)	0.027^a	0.666^a
AP (CCS), n(%)	0–1	38 (82.61%)	48 (78.69%)	43 (78.18%)	1.000^b	1.000^b
AP (CCS), n(%)	2	7 (15.22%)	13 (21.31%)	12 (21.82%)	1.000^b	1.000^b
NYHA, n(%)	1	13 (28.26%)	14 (22.95%)	20 (36.36%)	1.000^b	1.000^b
	2	31 (67.39%)	44 (72.13%)	31 (56.36%)
	3	2 (4.35%)	3 (4.92%)	4 (7.27%)

ISSN: 1471-2261